Trials / Withdrawn
WithdrawnNCT06710197
IL-1 Inhibition in Early TNBC
IL-1 Inhibition for Patients With Early Stage Triple Negative and ER-low Breast Cancer: a Window-of-opportunity Study
- Status
- Withdrawn
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 0 (actual)
- Sponsor
- University Health Network, Toronto · Academic / Other
- Sex
- Female
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This study will examine changes in the tumor microenvironment (TME) induced by 14 days of pre-operative IL-1-inhibiting therapy among patients with early breast cancer (including TNBC and ER-low positive). Key immune biomarkers (TILs, TAMs, NK cells, IL1\[beta\] and inflammasome component expression) will be evaluated at baseline and following 14 days of IL-1 antagonist therapy (Anakinra) using paired tissue specimens.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Anakinra (Kineret®) | 100 mg/daily subcutaneously |
Timeline
- Start date
- 2025-03-05
- Primary completion
- 2026-02-12
- Completion
- 2026-02-12
- First posted
- 2024-11-29
- Last updated
- 2026-03-05
Locations
1 site across 1 country: Canada
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT06710197. Inclusion in this directory is not an endorsement.